



## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449

ATTY. DOCKET NO.

03678.0064.US00

APPLICATION NO.

09/643,138

APPLICANT

Jose L. BOYER, et al.

FILING DATE

August 21, 2000

GROUP

1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PL	1.	5,049,550	09/17/91	Zamecnik	514	47	11/21/88
	2.	5,292,498	03/08/94	Boucher	424	45	06/19/91
	3.	5,596,088	01/21/97	Boucher, et al.	536	23.5	05/16/95
	4.	5,607,836	03/04/97	Boucher, et al.	435	7.2	05/19/95
	5.	5,628,984	05/13/97	Boucher	424	45	07/31/95
	6.	5,635,160	06/03/97	Stutts, et al.	424	45	06/07/95
	7.	5,656,256	08/12/97	Boucher, et al.	424	45	12/14/94
	8.	5,681,823	10/28/97	Kim, et al.	514	47	05/02/96
	9.	5,691,156	11/25/97	Boucher, et al.	435	7.21	05/19/95
	10.	5,763,447	06/09/98	Jacobus, et al.	514	265	07/23/96
	11.	5,789,391	08/04/98	Jacobus, et al.	514	51	07/03/96
	12.	5,837,861	11/17/98	Pendergast, et al.	536	25.6	02/10/97
	13.	5,900,407	05/04/99	Yerxa, et al.	514	47	02/06/97
	14.	5,902,567	05/11/99	Boucher	424	9.1	12/30/96
	15.	5,935,555	08/10/99	Stutts, et al.	424	45	05/08/97
	16.	5,958,897	09/28/99	Jacobus, et al.	514	49	01/09/98
	17.	5,962,432	10/05/99	LaCroix, et al.	514	47	07/03/96
	18.	5,968,913	10/19/99	LaCroix, et al.	514	47	12/23/97
	19.	5,972,904	10/26/99	Jacobus, et al.	514	51	01/09/98
	20.	5,981,506	11/09/99	Jacobus, et al.	514	47	01/09/98
	21.	6,022,527	02/08/00	Boucher, et al.	424	45	07/13/99
	22.	6,037,343	03/14/00	El-Fehail Ali	514	252	12/22/95
	23.	6,040,317	03/21/00	Duggan, et al.	514	317	12/28/98
	24.	6,133,247	10/17/00	Boucher, et al.	514	50	01/22/97
PL	25.	6,143,279	11/07/00	Boucher, et al.	424	45	08/28/98
PL	26.	6,159,952	12/12/00	Shaffer, et al.	514	47	11/07/96

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Patricia Lew*

1-10-06

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

**PTO FORM 1449**

ATTY. DOCKET NO.

03678.0064.US00

APPLICATION NO.

09/643,138

APPLICANT

Jose L. BOYER, et al.

FILING DATE

August 21, 2000

GROUP

1614

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
PL	27.	WO 00/30629	02/06/00	PCT			X	
	28.	WO 00/39145	06/07/00	PCT			X	
	29.	WO 00/50024	31/08/00	PCT			X	
	30.	WO 94/08593	28/04/94	PCT			X	
	31.	WO 95/10538	20/04/95	PCT			X	
	32.	WO 97/29456	21/08/97	PCT			X	
	33.	WO 97/35591	02/10/97	PCT			X	
	34.	WO 98/03177	29/01/98	PCT			X	
	35.	WO 98/03182	29/01/98	PCT			X	
	36.	WO 98/15835	16/04/98	PCT			X	
	37.	WO 98/19685	14/05/98	PCT			X	
	38.	WO 98/34593	13/08/98	PCT			X	
	39.	WO 98/34942	13/08/98	PCT			X	
	40.	WO 99/01138	14/01/99	PCT			X	
	41.	WO 99/05155	04/02/99	PCT			X	
	42.	WO 99/09998	04/03/99	PCT			X	
	43.	WO 99/32085	01/07/99	PCT			X	
PL	44.	WO 99/61012	02/12/99	PCT			X	

**OTHER REFERENCES**

(Including Author, Title, Date, Pertinent Pages, Etc.)

PL	45.	Antiplatelet Trialists' Collaboration., "Collaborative overview of randomised trials of antiplatelet therapy-I : Prevention of Death, myocardial Infarction, and stroke by prolonged antiplatelet therapy in various categories of patients," <i>Br. Med. J.</i> <u>308</u> : 81-106 (1994)
PL	46.	Antiplatelet Trialists' Collaboration., "Collaborative overview of randomised trials of antiplatelet - therapy-II : Maintenance of Vascular graft or arterial patency by antiplatelet therapy," <i>Br. Med. J.</i> <u>308</u> : 159-168 (1994)
PL	47.	Antman, E, for The TIMI 9a investigators, "Hirudin in Acute Myocardial Infarction," <i>Circulation</i> , <u>90</u> (4):1624-1630 (1994)

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Patricia Lee*

1-10-06

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>  <b>PTO FORM 1449</b>	ATTY. DOCKET NO. 03678.0064.US00	APPLICATION NO. 09/843,138
	APPLICANT Jose L. BOYER, et al.	
	FILING DATE August 21, 2000	GROUP 1614

R	48.	Bernat, A., et al., "Effect of Various Antiplatelet Agents on Acute Arterial Thrombosis in the Rat," <i>Thromb. Haemostas.</i> (1993) <u>70</u> (5):812-816
	49.	Bush, L., et al., "Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries," <i>Circulation</i> <u>69</u> (6):1161-1170, (1984)
	50.	EPIC investigators, "Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein lib/IIa Receptor in High-Risk Coronary Angioplasty," <i>New Engl. J. Med.</i> (1994) 330:956-961
	51.	Folts, J. et al., "Platelet Aggregation in Partially Obstructed Vessels and its Elimination with Asprian," <i>Circulation</i> <u>54</u> (3):365-370 (1976)
	52.	Frederick, L.G., et al., "The Protective Dose of the Potent GPIIb/IIIa Antagonist SC-54701A is Reduced When Used in Combination with Asprian and Heparin in a Canine Model of Coronary Artery Thrombosis," <i>Circulation</i> <u>93</u> (1):129-134 (1996)
	53.	Geiger, J., et al., "Specific Impairment of Human Platelet P2Y ac ADP Receptor-Mediated Signaling by the Antiplatelet Drug Clopidogrel," <i>Arterioscler. Thromb. Vasc. Biol.</i> <u>19</u> :2007-2011 (1999)
	54.	GUSTO Iia Investigators, The Global Use of Strategies to Open Occluded Coronary Arteries., "Randomized Trial of Intravenous Heparin Versus Recombinant Hirudin for Acute Coronary Syndromes", <i>Circulation</i> . <u>90</u> (4): 1631-1637 (1994)
	55.	Hass, W., et al., "A Randomized Trial Comparing Ticlopidine Hydrochloride with Asprian for the Prevention of Stroke for High-Risk Patients," <i>N. Engl. J. Med.</i> , <u>321</u> (8):501-507 (1989)
	56.	Herbert, J.M. et al., Inhibitory Effect of Clopidogrel on Platelet Adhesion and Intimal Proliferation After Arterial Injury in Rabbits," <i>Arterioscl. Thromb.</i> (1993) <u>13</u> (8):1171-1179
	57.	Hourani, et al., The Platelet ADP Receptors Meeting, La Thuile, Italy, March 29-31, 2000
	58.	Humphries, R.G., et al., "Pharmacological profile of the novel P2T-Purinoreceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vitro," <i>Br. J. Pharmacol.</i> <u>115</u> :1110-1116 (1995)
	59.	Ingall, A., et al., "Antagonists of the Platelet P2t Receptor: A Novel Approach to Antithrombotic Therapy," <i>J. Med. Chem.</i> <u>42</u> : 213-220 (1999)
	60.	Lazarowski, E., et al., "Pharmacological selectivity of the cloned human P2u-purinoreceptor: potent activation by diadenosine tetraphosphate," <i>Brit. J. Pharm.</i> <u>116</u> :1619-1627 (1995)
	61.	Lekstrom, J and William R. Bell, "Asprian in the Prevention of Thrombosis," <i>Medicine</i> <u>70</u> (3):161-178 (1991)
	62.	Maffrand, J.P., et al., "ADP Plays a Key Role in Thrombogenesis in Rats," <i>Thromb. Haemostas.</i> (1988) <u>59</u> (2):225-230
v	63.	Mickelson, J.K., et al., "Antiplatelet Antibody [7E3 F(ab')2] Prevents Rethrombosis After Recombinant Tissue-Type Plasminogen Activator-Induced Coronary Artery Thrombolysis in a Canine Model," <i>Circulation</i> <u>81</u> (2):617-627 (1990)
RL		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Patricia Lee* 1-10-06

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>  <b>PTO FORM 1449</b>	ATTY. DOCKET NO. 03678.0064.US00	APPLICATION NO. 09/643,138
	APPLICANT Jose L. BOYER, et al.	
	FILING DATE August 21, 2000	GROUP 1614

fL	64.	Neuhaus., K. L. et al., "Safety Observations from the Piolet Phase of the Randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) Study," <i>Circulation</i> , <u>90</u> (4): 1638-1642 (1994)
	65.	Olivier, K., et al., "Acute Safety and Effects on Mucociliary Clearance of Aerosolized Urdine 5' - Triphosphate + Amiloride in Normal Human Adults," - <i>Am. J. Respir. Crit. Care Med.</i> <u>154</u> :217-223 (1996)
	66.	Quinn, M and Desmond J. Fitzgerald, "Ticlopidine and Clopidogrel," <i>Circulation</i> <u>100</u> (15):1667-1672 (1999)
	67.	Romson, J., et al., "Electrical Induction of Coronary Artery Thrombosis in the Ambulatory Canine: A model for IN VIVO Evaluation of Anti-Thrombotic Agents," <i>Thromb. Res.</i> <u>17</u> :841-853 (1980)
	68.	Shebuski, R., et al., "Acceleration of Recombinant Tissue-Type Plasminogen Activator-Induced Thrombolysis and Prevention of Reocclusion by the Combination of Heparin and the Arg-Gly-Asp-Containing Peptide Bitistatin in a Canine Model of Coronary Thrombosis," <i>Circulation</i> <u>82</u> (1):169-177 (1990)
V	69.	Tschopp, J.F., et al., "Inhibition of coronary artery reocclusion after thrombolysis with an RGD-containing peptide with no significant effect on bleeding time," <i>Coron. Artery Dis.</i> <u>4</u> :809-817(1993)
fL	70.	Weber, M., et al., "Low-Dose Aspirin Verses Anticoagulants for Prevention of Coronary Graft Occlusion," <i>Am. J. Cardiol.</i> <u>66</u> :1461-1468 (1990)

*Patricia Lewis* 1-10-06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.